Technical Analysis for FTSV - Forty Seven, Inc.

Grade Last Price % Change Price Change
grade C 45.74 11.15% 4.59
FTSV closed up 11.15 percent on Friday, January 17, 2020, on 1.88 times normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical FTSV trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
Medicine Cancer Medical Specialties Immunology Cancers Monoclonal Antibodies Cancer Immunotherapy Acute Myeloid Leukemia Ovarian Cancer Lymphoma Cancer Research Humanized Antibody NHL CD47

Is FTSV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 49.5
52 Week Low 5.53
Average Volume 956,882
200-Day Moving Average 14.43
50-Day Moving Average 26.50
20-Day Moving Average 39.73
10-Day Moving Average 37.85
Average True Range 3.12
ADX 45.54
+DI 46.36
-DI 15.82
Chandelier Exit (Long, 3 ATRs ) 40.14
Chandelier Exit (Short, 3 ATRs ) 41.65
Upper Bollinger Band 46.49
Lower Bollinger Band 32.96
Percent B (%b) 0.94
BandWidth 34.05
MACD Line 3.28
MACD Signal Line 3.80
MACD Histogram -0.5261
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.53
Resistance 3 (R3) 56.58 53.04 54.73
Resistance 2 (R2) 53.04 50.29 53.01 54.13
Resistance 1 (R1) 49.39 48.60 51.22 49.34 53.53
Pivot Point 45.85 45.85 46.76 45.82 45.85
Support 1 (S1) 42.20 43.10 44.03 42.15 37.95
Support 2 (S2) 38.66 41.41 38.63 37.35
Support 3 (S3) 35.01 38.66 36.75
Support 4 (S4) 34.96